Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms

Journal of Clinical Investigation

Volumn 115, Issue 9, 2005, Pages 2351-2362

  Fütterer, Agnes ^a   Campanero, Miguel R ^a   Leonardo, Esther ^a   Criado, Luis M ^a   Flores, Juana M ^b   Hernández, Jesús M ^c   San Miguel, Jesus F ^c   Martinez A, Carlos ^a,d  

^a CSIC   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Centro de Investigacion del Cancer   (Spain)

^d CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE; PROTEIN DIDO; PROTEIN DIDO1; PROTEIN DIDO2; PROTEIN DIDO3; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CELL HETEROGENEITY; CHROMOSOME 20Q; CHRONIC DISEASE; CONTROLLED STUDY; DEATH INDUCER OBLITERATOR GENE; DIDO GENE; DISEASE MODEL; GENE; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MAPPING; GENETIC DISORDER; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MOUSE; MYELODYSPLASIA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL TIME; SYMPTOMATOLOGY; TARGET CELL; TUMOR SUPPRESSOR GENE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; BONE MARROW; CELL LINE; CHROMOSOMES, HUMAN, PAIR 20; CLONING, MOLECULAR; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; GENE TARGETING; HEMATOLOGIC NEOPLASMS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROTEIN ISOFORMS; SEQUENCE ALIGNMENT; SPLEEN; SURVIVAL RATE; TRANSCRIPTION FACTORS;

EID: 24644453436     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI24177     Document Type: Article

References (50)

1. Van Etten, R.A., and Shannon, K.M. 2004. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 6:547-552.
2. Vardiman, J.W., Harris, N.L., and Brunning, R.D. 2002. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 100:2292-2302.
3. Greenberg, P.L., Young, N.S., and Gattermann, N. 2002. Myelodysplastic syndromes [review]. Hematology (Am. Soc. Hematol. Educ. Program). 2002:136-161.
4. Dicksteien, J.I., and Vardiman, J.W. 1995. Hematopathologic findings in the myeloproliferative disorders. Semin. Oncol. 22:355-373.
5. Imbert, M. 2002. Peripheral blood findings in chronic myeloproliferative disorders. Clin. Lab. Med. 22:137-153.
6. Stewart, K., Carstairs, K.C., Dube, I.D., and Keating, A. 1990. Neutrophilic myelofibrosis presenting as Philadelphia chromosome negative BCR non-rearranged chronic myeloid leukemia. Am. J. Hematol. 34:59-63.
7. Thiele, J., Fohlmeister, I., Vonneguth, B., Zankovich, R., and Fischer, R. 1986. The prognostic implication of clinical and histological features in Ph1+ chronic myelocytic leukaemia (CML). Anticancer Res. 6:1401-1409.
8. Arceci, R.J., Longley, B.J., and Emanuel, P.D. 2002. Atypical cellular disorders [review]. Hematology (Am. Soc. Hematol. Educ. Program). 2002:297-314.
9. Del Canizo, M.C., et al. 1998. The value of cell cultures for the diagnosis of mixed myelodysplastic/myeloproliferative disorders. Haematologica. 83:3-7.
10. Neuwirtova, R., et al. 1996. Mixed myelodysplastic and myeloproliferative syndromes. Leuk. Res. 20:737-726.
11. Shih, L.Y., Chiu, W.F., and Lee, C.T. 1991. Diagnostic and prognostic values of in vitro culture growth patterns of marrow granulocyte-macrophage progenitors in patients with myelodysplastic syndrome. Leukemia. 5:1092-1098.
12. Mesa, R.A. 2002. Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders. Int. J. Hematol. 76(Suppl. 2):193-203.
13. Steensma, D.P., Tefferi, A., and Li, C.Y. 2003. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk. Res. 27:775-782.
14. Foa, P., et al. 1991. Chronic neutrophilic leukaemia associated with polycythemia vera: pathogenetic implications and therapeutic approach. Br. J. Haematol. 78:286-288.
15. Ohyashiki, K., et al. 1993. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two? Leukemia. 7:338-340.
16. Shamdas, G.J., Spier, C.M., and List, A.F. 1993. Myelodysplastic transformation of polycythemia vera: case report and review of the literature [review]. Am. J. Hematol. 37:45-48.
17. Verhoef, G.E., Demuynck, H., Zachee, P., and Boogaerts, M.A. 1994. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two [review]? Leukemia. 8:714-735.
18. Kogan, S.C., et al. 2002. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 100:238-245.
19. Melo, J.V. 1996. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood. 88:2375-2384.
20. Dewald, G.W., Schad, C.R., Lilla, V.C., and Jalal, S.M. 1993. Frequency and photographs of HGM11 chromosome anomalies in bone marrow samples from 3,996 patients with malignant hematologic neoplasms. Cancer Genet. Cytogenet. 68:60-69.
21. Asimakopoulos, F.A., White, N.J., Nacheva, E., and Green, A.R. 1994. Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes. Blood. 84:3086-3094.
22. Mitelman, F., Mertens, F., and Johansson, B. 1997. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat. Genet. 15:417-474.
23. Davis, M.P., Dewald, G.W., Pierre, R.V., and Hoagland, H.C. 1984. Hematologic manifestations associated with deletions of the long arm of chromosome 20. Cancer Genet. Cytogenet. 12:63-71.
24. Braun, B.S., et al. 2004. Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl. Acad. Sci. U. S. A. 101:597-602.
25. Ishida, D., et al. 2003. Myeloproliferative stem cell disorders by deregulated Rap1 activation in SPA-1-deficient mice. Cancer Cell. 4:55-65.
26. Kometani, K., Ishida, D., Hattori, M., and Minato, N. 2004. Rap1 and SPA-1 in hematologic malignancy. Trends Mol. Med. 10:401-408.
27. Le, D.T., et al. 2004. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood. 103:4243-4250.
28. Garcia-Domingo, D., et al. 1999. DIO-1 is a gene involved in onset of apoptosis in vitro, whose misexpression disrupts limb development. Proc. Natl. Acad. Sci. U. S. A. 96:7992-7997.
29. Bollag, G., et al. 1996. Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat. Genet. 12:144-148.
30. Largaespada, D.A., Brannan, C.I., Jenkins, N.A., and Copeland, N.G. 1996. Nf1 deficiency causes Ras-mediated granulocyte/macrophage colony stimulating factor hypersensitivity and chronic myeloid leukaemia. Nat. Genet. 12:137-143.
31. Fenske, T.S., et al. 2004. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. Proc. Natl. Acad. Sci. U. S. A. 101:15384-15189.
32. Higuchi, M., et al. 2002. Expression of a conditional AML1-ETO oncogene bypasses embryonic lethality and establishes a murine model of human t(8;21) acute myeloid leukemia. Cancer Cell. 1:63-74.
33. Buonamici, S., et al. 2004. EVI1 induces myelodysplastic syndrome in mice. J. Clin. Invest. 114:713-719. doi:10.1172/JCI200421716.
34. Miyauchi, J., et al. 1994. Mutations of the N-ras gene in juvenile chronic myelogenous leukemia. Blood. 83:2248-2254.
35. Parker, J., and Mufti, G.J. 1996. Ras and myelodysplasia: lessons from the last decade [review]. Semin. Hematol. 33:206-224.
36. Shannon, K.M., et al. 1994. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med. 330:597-601.
37. Side, L.E., et al. 1998. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood. 92:267-272.
38. Tartaglia, M., et al. 2003. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acure myeloid leukemia. Nat. Genet. 34:148-150.
39. Fodde, R., and Smits, R. 2002. Cancer biology. A matter of dosage. Science. 298:761-763.
40. Islam, M.Q., and Islam, K. 2000. A new functional classification of tumor-suppressing genes and its therapeutic implications. Bioessays. 22:274-285.
41. Knudson, A.G., Jr. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. U. S. A. 68:820-823.
42. Jacks, T., et al. 1992. Effects of an Rb mutation in the mouse. Nature. 359:295-300.
43. White, N.J., et al. 1994. Deletion of chromosome 20q in myelodysplasia can occur in a multipotent precursor of both myeloid cells and B cells. Blood. 83:2809-2816.
44. Holtschke, T., et al. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 87:307-317.
45. Paige, A.J. 2003. Redefining tumour suppressor genes: exceptions to the two-hit hypothesis [review]. Cell. Mol. Life Sci. 60:2147-2163.
46. Milner, G.R., et al. 1977. Bone marrow culture studies in refractory cytopenia and 'smouldering leukaemia'. Br. J. Haematol. 35:251-261.
47. Spitzer, G., Verma, D.S., Dicke, K.A., Smith, T., and McCredie, K.B. 1979. Subgroups of oligoleukemia as identified by in vitro agar culture. Leuk. Res. 3:29-39.
48. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T., and Mulligan, R.C. 1991. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 65:1153-1163.
49. Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., and Roder, J.C. 1993. Derivation of completely cell culture-derived mice from early-passage embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 90:8424-8428.
50. Sambrook, J., Fritsch, E.F., and Maniatis, T. 1989. Extraction, purification, and analysis of messenger RNA from eukaryotic cells. In Molecular cloning: a laboratory manual. 2nd edition. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York, USA. 7.1-7.87.